Literature DB >> 3668853

Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil.

J E Chelly1, D C Hill, D R Abernethy, A Dlewati, M F Doursout, R G Merin.   

Abstract

Lidocaine (3 mg/kg i.v.) injected during steady-state verapamil infusions (3 micrograms/kg i.v.) induced slight and transient hemodynamic changes in nine conscious dogs. Systemic vascular resistance and left ventricular dP/dt decreased by 16% from 41 +/- 4 mm Hg/liter/min and by 20% from 2876 +/- 137 mm Hg/sec, respectively, whereas heart rate and cardiac output increased by 18% from 100 +/- 5 beats/min and by 17% from 2.5 +/- 0.2 liters/min, respectively. Simultaneously, lidocaine induced a transient but more pronounced decrease in verapamil plasma concentration of 48% from 60 +/- 3 ng/ml. This pharmacokinetic interaction was not the result of a lidocaine-induced decrease in the fraction of verapamil bound to plasma protein because in vitro lidocaine failed to displace verapamil from its protein binding site. Moreover, an increase in verapamil total clearance was not the only mechanism because steady-state lidocaine (6 mg/kg over 5 min followed by 60 micrograms/kg/min) in the presence of steady-state verapamil (200 micrograms/kg over 3 min followed by 3 micrograms/kg/min) also resulted in a transient decrease in verapamil plasma concentration from 59 +/- 9 to 23 +/- 2 ng/ml in six conscious dogs. Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668853

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

2.  Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.

Authors:  H J Kang; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

3.  A pilot study evaluating biomarker development for drug-induced chronic eczematous eruptions of aging individuals.

Authors:  Erika Mae Summers; Nicholas Ray Blickenstaff; Garrett Curtis Coman; Thomas Bernd Martins; Harry Raymond Hill; Richard Dennis Sontheimer
Journal:  Ann Transl Med       Date:  2017-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.